Suraksha Diagnostic Q2 FY27 PAT Rises 69% to INR149.5 Million
Key highlights
- Suraksha Diagnostic reported Q2 FY27 total income of INR1,005.7 million, up 26.4% year-on-year.
- Q2 FY27 EBITDA rose 45.4% year-on-year to INR363.2 million, lifting EBITDA margin to 36.7%.
- Q2 FY27 PAT increased 69.4% year-on-year to INR149.5 million.
- The network reached 77 centres after five additions in Q2 FY27, including entry into Jharkhand.
powered by IRIS

Suraksha Diagnostic Limited reported Q2 FY27 profit after tax of INR149.5 million, up 69% year-on-year, as total income increased 26.4% to INR1,005.7 million and EBITDA margin improved to 36.7%. The quarterly performance crossed the INR1,000 million income mark and reflected improving profitability at both mature and recently opened centres.
Know Suraksha Diagnostic inside out
Results, valuation, peers and who's buying, in one view.
What did Suraksha Diagnostic report in Q2 FY27?
Suraksha Diagnostic reported total income of INR1,005.7 million for Q2 FY27, compared with INR795.8 million in Q2 FY26. EBITDA rose to INR363.2 million from INR249.7 million a year earlier, while the EBITDA margin expanded by 500 basis points to 36.7% from 31.7%.
Profit after tax rose to INR149.5 million from INR88.28 million in the corresponding quarter of the previous year. The PAT margin stood at 15.1%. The pace of profit growth was higher than income growth, reflecting the reported margin expansion during the quarter.
The company also reported revenue from operations of INR991 million, up 25.9% year-on-year, and net profit of about INR150 million, up 70.5%, in its earnings-call summary. The reported figures are broadly consistent with the total income and PAT numbers released for the quarter.
What drove Suraksha Diagnostic's revenue and margin growth?
Suraksha Diagnostic attributed its growth to network expansion and the maturation of centres. The company served 0.42 million patients in Q2 FY27 and conducted 2.4 million tests, taking tests per patient to 5.7 during the quarter.
Management clarified during the earnings call that test volumes grew 9% year-on-year. Chief Executive Officer Ritu Mittal said an earlier press-release figure of 2.32 million tests was an error and had been corrected to 2.4 million. This clarification is important because the revised volume figure supports the reported improvement in patient-level operating metrics.
Revenue per patient was INR2,348 in Q2 FY27, while EBITDA per patient was INR861. For H1 FY27, the corresponding figures were INR2,335 and INR849, respectively. These metrics indicate that the business generated higher revenue and EBITDA per patient in the second quarter than the first-half average.
Mature centres recorded an EBITDA margin of 42% in Q2 FY27. Centres that were less than two years old posted an EBITDA margin of 11.8%, a significant improvement from a negative 16.8% in Q2 FY26. The change in the newer-centre margin was a key contributor to the broader improvement in profitability.
How is Suraksha Diagnostic expanding its network?
Suraksha Diagnostic ended H1 FY27 with 77 centres after commissioning five new centres during Q2 FY27. The company also entered Jharkhand during the quarter and said it was progressing with its plans for Tripura.
The expansion takes the diagnostic network beyond its established market in West Bengal. Management has described its approach as cluster-building, where a denser local network can support operations and improve the utilisation of centres as they mature. The available disclosures do not provide separate revenue or profit figures for Jharkhand or the planned Tripura operations.
New centres can initially carry lower utilisation and operating costs before reaching scale. The movement of the under-two-year-centre EBITDA margin into positive territory suggests that the newer facilities contributed more favourably in Q2 FY27 than in the previous-year quarter.
Got a follow-up? Ask IRIS
What is Suraksha Diagnostic's FY27 outlook and near-term risk?
Suraksha Diagnostic management guided for FY27 revenue growth of 15% to 18% and indicated that EBITDA margin could remain in the 34% to 35% range on a steady-state basis next year. Q2 revenue growth of 26.4% and the 36.7% EBITDA margin were above these stated medium-term guideposts, though quarterly performance can vary with seasonality.
Management expects Q3 FY27 revenue to decline because of the festive season. It indicated that revenue could fall by 4% to 5% from the Q2 level of about INR1,000 million. This is a seasonal expectation disclosed by the company rather than a change to its full-year growth guidance.
The execution of the Jharkhand entry and Tripura plans remains relevant for investors assessing the expansion strategy. New geographies require the company to build patient awareness, referral relationships and centre utilisation, while maintaining the operating discipline that supported the Q2 margin improvement.
How do the Q2 results matter for investors and the diagnostics sector?
The Q2 results show that Suraksha Diagnostic combined double-digit income growth with a faster increase in EBITDA and PAT. Its 42% mature-centre EBITDA margin and the shift to an 11.8% margin at newer centres provide operating evidence for the company’s stated focus on centre maturation and network efficiency.
For investors, the disclosed Q3 seasonal decline is a near-term consideration alongside the FY27 growth target. The reported performance does not establish a future share-price outcome, but it provides measurable indicators to track: patient volumes, tests per patient, revenue per patient, centre additions and profitability at recently opened facilities.
The diagnostic-services sector depends on patient footfall, test mix, network reach and centre-level utilisation. Suraksha Diagnostic's disclosed demand visibility in genomics and specialised diagnostics points to areas of focus, but the company did not disclose a separate financial contribution from these service lines in the material provided.
Conclusion
Suraksha Diagnostic's Q2 FY27 results were marked by total income exceeding INR1,000 million, EBITDA margin rising to 36.7%, and PAT increasing 69% to INR149.5 million. Higher patient-level revenue and EBITDA, along with a sharp improvement in margins at newer centres, supported the quarter's financial performance.
The next disclosed item to watch is Q3 FY27 performance, when management expects festive seasonality to reduce revenue by 4% to 5% from the Q2 level. Investors can also monitor progress in Jharkhand, the proposed Tripura expansion, and whether the company delivers its FY27 revenue-growth guidance of 15% to 18%.


